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Bone marrow is the primary site of metastasis in pa-
tients with advanced stage prostate cancer. Prostate
carcinoma cells metastasizing to bone must initially ad-
here to endothelial cells in the bone marrow sinusoids.
In this report, we have modeled that interaction in vitro
using two bone marrow endothelial cell (BMEC) lines
and four prostate adenocarcinoma cell lines to investi-
gate the adhesion mechanism. Highly metastatic PC3
and PC3M-LN4 cells were found to adhere rapidly and
specifically (70–90%) to BMEC-1 and trHBMEC bone
marrow endothelial cells, but not to human umbilical
vein endothelial cells (15–25%). Specific adhesion to
BMEC-1 and trHBMEC was dependent upon the pres-
ence of a hyaluronan (HA) pericellular matrix assem-
bled on the prostate carcinoma cells. DU145 and LNCaP
cells were only weakly adherent and retained no cell
surface HA. Maximal BMEC adhesion and HA encapsu-
lation were associated with high levels of HA synthesis
by the prostate carcinoma cells. Up-regulation of HA
synthase isoforms Has2 and Has3 relative to levels ex-
pressed by normal prostate corresponded to elevated
HA synthesis and avid BMEC adhesion. These results
support a model in which tumor cells with up-regulated
HA synthase expression assemble a cell surface hyaluro-
nan matrix that promotes adhesion to bone marrow en-
dothelial cells. This interaction could contribute to pref-
erential bone metastasis by prostate carcinoma cells.
Prostate cancer is the second leading cause of cancer death in
men (1). In metastatic prostate cancer, peripheral tumor cells
undergo phenotypic changes that facilitate invasion of surround-
ing organ tissues, entry into the lymphatic system and/or the
bloodstream, and colonization of other tissues in the body. Their
ability to establish growth in a remote site is dependent upon a
specific recognition process involving an initial rapid adhesion of
the circulating tumor cell to endothelial cells lining the bone
marrow microvasculature (2), transmigration through the endo-
thelial cell barrier, and subsequent lodgment in the stroma (3, 4).
Remote metastases in prostate cancer often occur in bone mar-
row, suggesting tissue or endothelial cell-specific factors may
contribute to prostate cancer metastasis to bone (2, 5).
Bone marrow endothelial cells (BMEC)1 maintain a special-
ized endothelium that must allow cell trafficking in and out of
the bone marrow (3, 4, 6). In addition to regulating the egress
of mature myeloid and lymphoid cells, BMEC selectively allow
transmigration of progenitor cells from a circulating popula-
tion, indicating that specific receptors regulate the movement
of cells through the endothelium (7). Studies have shown that
the transmigrating cells move directly through an endothelial
cell in a process that involves specific adhesive interactions
(Ref. 3 and references therein). BMEC constitutively express
adhesion receptors such as VCAM-1 (8, 9), E-selectin (9), and
P-selectin (10), which are not expressed in large vein endothe-
lia unless activated by cytokines (6). Specific adhesive interac-
tions between hemopoietic cells and BMEC thought to be im-
portant for homing include endothelial lectins and progenitor
glycoproteins (11–14), VCAM/VLA-4 (11–13), and CD44/hyalu-
ronan (15). Initial adhesion may be mediated primarily
through selectins and glycoproteins. BMEC-associated chemo-
kines such as SDF-1 (stromal-derived factor) can then stimu-
late integrin ligation, leading to progenitor arrest (16, 17).
Because the bone marrow microvasculature presents the
first site of interaction for circulating tumor cells metastasizing
to the bone marrow, it is likely that mechanisms of metastasis
may parallel those employed by homing progenitors. In fact,
tumor cells have been shown to bind and transmigrate through
BMEC (17–19). The adhesion molecules implicated in these
processes, CD44/hyaluronan, VLA-4/VCAM, and LFA-1/ICAM,
are also involved in homing and extravasation of circulating
lymphocytes and progenitor cells.
Hyaluronan (HA) is a ubiquitous high molecular weight gly-
cosaminoglycan polymer required for growth, development, cell
motility, and cushioning of joints (20, 21). Elevated levels of HA
are associated with various pathologies, such as arthritis, in-
flammation, and several cancers (22–24), including prostate
(25, 26). Melanoma cells selected for high expression of HA
were more metastatic when injected into nude mice than cells
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that expressed low amounts of HA (27). Furthermore, overex-
pression of HA biosynthetic enzymes in tumor cell lines has
been shown to increase tumorigenicity and metastatic poten-
tial (28, 29).
To investigate the molecular mechanism of initial adhesion
to bone marrow endothelium, we modeled adhesion in vitro
using the bone marrow endothelial cell lines BMEC-1 and
trHBMEC and four prostate adenocarcinoma cell lines, PC3,
PC3M-LN4, DU145, and LNCaP. Highly metastatic PC3 and
PC3M-LN4 cells adhered rapidly to BMEC-1 but not to large
vein endothelial cells (HUVEC). DU145 and LNCaP cells, in
contrast, were poorly adherent to endothelial cells. Maximal
BMEC adhesion was inhibited by addition of excess exogenous
hyaluronan, and by hyaluronidase digestion of pericellular HA,
found assembled specifically on PC3 and PC3M-LN4 cells.
Presence of pericellular HA was correlated with elevated levels
of HA synthesis and expression of HA synthase. Our data
relate HA synthase overexpression to metastatic potential of
prostate tumor cells and represent the first report of such a
correlation. Collectively, our results implicate tumor cell-asso-
ciated HA and up-regulation of HA synthase in prostate cancer
progression and may directly impact metastatic potential or
preferential tissue colonization of individual tumor cells.
EXPERIMENTAL PROCEDURES
Cell Culture and Reagents—PC3, DU-145, and LNCaP human pros-
tate adenocarcinoma cell lines were purchased from ATCC (Manassas,
VA). PC3 and DU145 cells were maintained in MEM supplemented
with 10% FBS, 1 mM sodium pyruvate and non-essential amino acids.
LNCaP cells were cultured in RPMI containing 10% FBS. The PC3
derivative cell line, PC3M-LN4, was kindly provided by Dr. Isaiah J.
Fidler (M. D. Anderson Hospital Cancer Center, Houston, TX), and was
maintained in the media described above for PC3 cells. Prostate carci-
noma cells were plated 2 days prior to experiments and used at ;70%
confluence. The BMEC-1 human bone marrow endothelial cell line was
a gift from Dr. S. Rafii (Cornell University Medical Center, New York,
NY) and were maintained in M199 containing 20% FBS (30). trHBMEC
human bone marrow endothelial cells were a gift from Dr. Karin
Schweitzer (Free University Hospital Amsterdam, The Netherlands)
and were maintained in RPMI containing 10% FBS (11). HUVEC were
purchased from Clonetics and cultured in endothelial cell growth me-
dium, EGM-2, as recommended by the vendor. Human bone marrow
stromal cells (31) were cultured and generously provided by Nisha Shah
and Dr. Tucker LeBien (University of Minnesota, Minneapolis, MN).
Aggrecan was prepared as previously described (32) from Swarm rat
chondrosarcoma.
Cell Adhesion Assay—Subconfluent prostate carcinoma cells were
PBS-EDTA-released, washed with adhesion medium (RPMI with 0.1%
BSA and 20 mM Hepes, pH 7.4, maintained throughout the assay at
37 °C), and resuspended at 1 3 106 cells/ml in adhesion medium. Cells
were incubated with 25 mg/ml calcein-AM (Molecular Probes, Eugene,
OR), a compound that is converted to a fluorophore only upon uptake
and metabolism by living cells, for 20 min, washed with adhesion
medium, and resuspended at 1 3 105 cells/ml. BMEC-1 or HUVEC were
seeded 100% confluent (about 40,000 cells/well) in 48-well plates for 2
days and washed twice with adhesion medium prior to the assay.
trHBMEC were similarly prepared, but seeded only overnight prior to
the assay. Prostate carcinoma cells (300 ml/well) were added to the
confluent endothelial cell monolayers and incubated for 12 min at 37 °C
unless otherwise indicated. Non-adherent cells were removed with two
gentle washes of adhesion medium. Viability of non-adherent cells was
verified by trypan blue exclusion. Adherent cells were solubilized with
PBS containing 0.2 N NaOH/1% SDS and quantified in a Cytofluor II
fluorescence plate reader at 485/530 nm (Biosearch Inc., Bedford, MA).
Inhibition of Cell Adhesion—Calcein-AM-labeled prostate carcinoma
cell suspensions, at 5 3 105 cells/ml, were preincubated with 16
units/ml Streptomyces hyaluronidase (HAase, Calbiochem, San Diego,
CA) for 25 min and diluted to 1 3 105 cells/ml with adhesion medium
prior to the assay. BMEC-1 monolayers were pretreated with 16
units/ml HAase in adhesion medium for 25 min where indicated. In the
case of determining the cell type retaining surface HA, the HAase was
removed from each cell type before the assay. In the other experiments,
the HAase was present throughout the assay.
To determine the effect of exogenous HA on intercellular adhesion,
trHBMEC were seeded at 100% confluence overnight in 48-well tissue
culture plates. Prior to the assay, the cell monolayers were washed
twice in adhesion medium and preincubated for 30 min in 100 ml of
adhesion medium containing the indicated concentrations of high mo-
lecular weight human umbilical cord HA (Sigma H1751). Prostate car-
cinoma cells were labeled and pretreated in the absence or presence of
HAase as described above. Labeled cells were then washed, resus-
pended in adhesion medium containing the appropriate concentration
of HA, and immediately added to the endothelial cell monolayers
(30,000 cells/well).
Particle Exclusion Assay—Pericellular HA matrices were visualized
as described previously (33). Briefly, prostate carcinoma cells cultured
in 48-well plates overnight prior to the assay were treated for 25 min in
the absence or presence of 16 units/ml Streptomyces hyaluronidase in
phenol red-free MEM with 0.1% BSA at 37 °C. This medium was re-
moved and cells were incubated 90 min with 2 mg/ml aggrecan in
MEM/0.1% BSA at 37 °C. The aggrecan solution was removed and 1 3
108 glutaraldehyde-fixed sheep red blood cells (Accurate Chemical and
Scientific Corp.) in PBS/1% BSA were added, allowed to settle for 15
min and then viewed with phase-contrast microscopy. The HA matrix
was evidenced by halos surrounding the cells from which the fixed
erythrocytes were excluded. Representative cells were photographed at
4003 magnification. To quantify matrix retention, outlines of matrices
and cellular boundaries from 20 individual cells of each type were
traced and relative areas calculated using IMAGE software (National
Institutes of Health). Relative matrix areas from similar tracings of
each cell type following HAase digestion were subtracted, and HA
matrix thickness was reported as the ratio of matrix area to cell area for
each cell type. A ratio of 1 indicates complete absence of pericellular
clearing.
HA Synthesis Quantitation—The concentration of HA in cell culture
supernatants was determined in a competitive binding assay (34). 96-
well Immulon microtiter plates were coated with human umbilical cord
HA at 25 mg/ml in 200 mM carbonate buffer (pH 9.6) for 4 h at 37 °C.
Excess HA was removed with four washes of PBS/0.05% Tween 20.
Prostate carcinoma cells (5000/well) were plated overnight in 12-well
plates. 24-h conditioned culture media were harvested, and cell counts
were determined by trypsin release and manual counting in a hemacy-
tometer. Serial dilutions of cell culture supernatant (100 ml of total
volume in PBS/Tween 20) were combined with 100 ml of a 1 mg/ml
solution of biotinylated hyaluronic acid-binding protein (Seikagaku)
and incubated in the HA-precoated wells at room temperature over-
night. The plate was washed 43 with PBS/Tween 20, developed using
an avidin-biotin HRP system (Vector Laboratories ABC-HRP kit PK-
4000) with OPD (Sigma P8287) as substrate, and read at 490 nm. HA
concentration was interpolated from a standard curve generated by
plotting HA standards against absorbance values. The mean HA con-
centration for each sample of culture supernatant was calculated, and
the results were normalized to cell number. Data are presented as mass
of HA (in mg) per 106 cells.
Determination of HA Synthase Expression—HA synthase isoform
and relative level of expression in prostate carcinoma cell lines was
semi-quantitatively assayed by RT-PCR. Poly(A)1 RNA was isolated
from subconfluent PC3M-LN4, PC3, DU145, and LNCaP cell lines with
the Oligotex mRNA isolation kit (Qiagen) and quantitated by Ribogreen
fluorescence (Molecular Probes). Normal prostate poly(A)1 RNA was
purchased from CLONTECH. 25 ng of each mRNA template was re-
verse-transcribed with an oligo(dT) primer using the Superscript II first
strand cDNA synthesis kit (Life Technologies, Inc.). PCR oligonucleo-
tides specific for Has1, Has2, and Has3 messages were designed from
the sequence data base; exact sequences are given in Table I along with
relative positions in the reported sequences and expected product sizes.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was amplified
with each reaction to standardize conditions using oligos available from
Life Technologies. Cycling conditions for Has2 and Has3 were opti-
mized independently as follows: 1-min initial denaturation at 95 °C; 33
cycles (Has2) or 27 cycles (Has3) of 30-s denaturation, 30-s annealing at
60 °C, and 30-s polymerization at 72 °C; 5-min final extension at 72 °C.
15 ml of each reaction was electrophoresed on a 3% agarose gel, stained
with ethidium bromide, and digitally photographed. To determine rel-
ative expression levels, digital images were integrated using Molecular
Analyst software, and band intensities were normalized to the corre-
sponding GAPDH band. Levels are reported as the fold expression
relative to that determined for normal prostate.
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RESULTS
PC3M-LN4 Cells Adhere Rapidly and Specifically to
BMEC-1 Bone Marrow Endothelial Cells—Prostate adenocar-
cinoma cells have been reported to adhere preferentially to
bone marrow-derived microvascular endothelial cells relative
to endothelial cells from a large vein source (HUVEC). This
preference implies a specific intercellular recognition process
dictated in part by heterogeneous expression of endothelial cell
surface adhesion receptors. To investigate the molecular inter-
actions underlying this process, we initially chose PC3M-LN4,
a human prostate adenocarcinoma cell line derived from PC3
cells. This subline was clonally selected for enhanced meta-
static propensity in mice and, in particular, was shown to be
capable of metastasis to bone upon intracardial injection (35).
We determined a time course for adhesion of PC3M-LN4 cells
to BMEC-1 bone marrow endothelial cells and compared it with
adhesion to HUVEC. Within 10 min, 70% of the cells were
adherent on BMEC-1 relative to 16% on HUVEC (Fig. 1). After
30 min, nearly 100% of the cells adhered to BMEC-1 compared
with only 25% on HUVEC. PC3M-LN4 cells, therefore, demon-
strate preferential rapid adhesion to BMEC-1 bone marrow
microvascular endothelial cells.
Hyaluronan Presented by the Prostate Carcinoma Cells Me-
diates Adhesion to BMEC-1—Several surface-borne adhesion
molecules have been implicated in homing of circulating cells to
the bone marrow, including VLA-4 (a4b1 integrin), LFA-1 (aLb2
integrin), CD44 proteoglycan, and the high molecular weight
glycosaminoglycan hyaluronan (HA). Pretreatment of PC3M-
LN4 cells with blocking antibodies directed against a4, b1, aL,
or b2 integrin subunits, or against CD44, had no effect on
adhesion of these cells to BMEC-1 (data not shown). To assess
the relevance of HA to prostate carcinoma cell adhesion, we
pretreated PC3M-LN4 or BMEC-1 cells individually or simul-
taneously with hyaluronidase (HAase) enzyme and assayed
initial rapid adhesion at a 12-min time point. As above, ;70%
of PC3M-LN4 cells were adherent at this time point in the
absence of enzymatic digestion (Fig. 2). Pretreatment of
BMEC-1 cells with HAase had no effect on this adhesion. How-
ever, treatment of PC3M-LN4 or both cell types reduced adhe-
sion to about 35%, indicating that cell surface HA promotes this
rapid intercellular interaction. Furthermore, the HA required
for maximum adhesion is carried by the prostate carcinoma
cells.
HA-mediated Adhesion of Prostate Carcinoma Cells Is Spe-
cific for Bone Marrow-derived Endothelial Cells—Because en-
dothelial cell types of different origin exhibit differences in HA
binding (36), we assayed the specificity of hyaluronidase-sen-
sitive prostate tumor cell adhesion to endothelial cells. PC3M-
LN4 cells were preincubated in the absence or presence of
hyaluronidase and allowed to adhere to BMEC-1, HUVEC, or
bone marrow-derived stromal cells (BMSC). Consistent with
the above results, PC3M-LN4 cells adhered rapidly to BMEC-1
and adhesion was inhibited by 50% in the presence of HAase
(Fig. 3). Cells adhered weakly to HUVEC, and adhesion was
not inhibited by enzyme treatment. Although adhesion of
PC3M-LN4 cells to BMSC was efficient and rapid, it was not
inhibited by HAase digestion, suggesting cell surface HA was
not mediating this adhesion. Collectively, these results imply








Forward 59 CTGAGGATCCGTCTGTGACTCGGAC 39 737 246
Reverse 59 GACTAAGCTTCTAGAGGACCGCTG 39 963
HAS 2
Forward 59 GTATCAGTTTGGTTTACAATC 39 1441 207
Reverse 59 GCACCATGTCATATTGTTGTC 39 1648
HAS 3
Forward 59 GTGCAGTGTATTAGTGGGCCCT 39 839 414
Reverse 59 GCTGCACCGTCAGCAGGAAGAGG 39 1253
GAPDH
Forward 59 TGAAGGTCGGAGTCAACGGATTTGGT 39 44 982
Reverse 59 CATGTGGGCCATGAGGTCCACCAC 39 1026
FIG. 1. Time course for adhesion of PC3M-LN4 prostate carci-
noma cells to BMEC-1 and HUVEC. Calcein-AM-labeled PC3M-LN4
cells were added in a single cell suspension to confluent BMEC-1 (closed
symbols) or HUVEC (open symbols) monolayers in a 48-well plate. At
the indicated times, wells were washed to remove nonadherent cells,
and adherent cells were lysed and quantified in a fluorescence plate
reader. Results are presented as the mean percentage of input cells
from triplicate wells 6 standard error of the mean (S.E.).
FIG. 2. HA on the PC3M-LN4 cells is required for adhesion to
BMEC-1. BMEC-1 monolayers and/or calcein-AM-labeled PC3M-LN4
cell suspensions were treated where indicated with 16 units/ml hyalu-
ronidase for 25 min. The hyaluronidase was removed, and the PC3M-
LN4 cells were added to the BMEC-1 for 12 min at 37 °C. Nonadherent
cells were removed by washing, and adherent cells were quantified in a
fluorescence plate reader. Each bar represents the mean of triplicate
wells assayed 6 S.E., reported as percentage of input cells.
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lial cell types may dictate specific recognition of prostate car-
cinoma cells, although different molecules may dominate their
interactions with other bone marrow-derived cells.
Rapid, Specific Prostate Carcinoma Cell Adhesion to Bone
Marrow Endothelial Cells Is Differentially Sensitive to Hyalu-
ronidase and Exogenous Hyaluronan—To examine whether
HA would generally promote adhesion of prostate carcinoma
cell lines to bone marrow endothelial cells, we measured
HAase-sensitive BMEC-1 adhesion of the commercially avail-
able cell lines PC3, DU145, and LNCaP. As demonstrated
above with PC3M-LN4 cells, about 60–70% of PC3 cells ad-
hered to BMEC-1 monolayers and adhesion was inhibited 40–
50% by HAase treatment (Fig. 4A). In contrast, DU145 and
LNCaP cells adhered very poorly (about 25%), and the low level
of adhesion was not altered by HAase treatment. None of the
cell lines adhered well to HUVEC, and adhesion to HUVEC
was not sensitive to HAase (Fig. 4A, inset). These results were
replicated in similar experiments using another human bone
marrow endothelial cell line, trHBMEC. As presented in Fig.
4B, PC3 and PC3M-LN4 cells exhibited comparable levels of
HAase-sensitive adhesion to trHBMEC, whereas very few
DU145 or LNCaP cells were adherent, and their adhesion was
unaffected by HAase treatment. HA, therefore, is required for
maximal rapid interaction between prostate carcinoma cells
and bone marrow endothelial cells.
To further establish the requirement for direct HA recogni-
tion by the BMEC as a component of preferential adhesion to
prostate carcinoma cells, we pretreated trHBMEC monolayers
with increasing concentrations of exogenous high molecular
weight HA. PC3M-LN4 cells were incubated with or without
HAase, which was then removed. Cells were resuspended in
the respective concentrations of HA and added to the BMEC.
As before, about 80% of the cells were adherent after 12 min,
and adhesion was reduced to 35% by HAase digestion (Fig. 5).
Preincubation of the BMEC with 10 mg/ml of HA modestly
increased adhesion of untreated cells, but rather strikingly
increased adhesion of HAase-treated cells to about 60%. How-
ever, a dose-dependent inhibition was observed at higher con-
centrations, with adhesion almost completely inhibited at 500
mg/ml HA. This effect was more greatly manifested in HAase-
treated cells, suggesting the residual adhesion observed for
these cells may be due to incompletely digested HA or HA
resynthesis during the time of the assay. When DU145 cells
were similarly incubated with pretreated trHBMEC (Fig. 5,
inset graph), no effect of exogenous HA was observed. This
confirms that the inhibitory effect of HA is not occurring indi-
rectly by destabilizing the BMEC monolayer, and that other
receptor interactions are promoting the less rapid adhesion of
DU145 cells to BMEC.
Prostate Carcinoma Cell Surface HA Retention Correlates to
BMEC Adhesion—If HA was mediating the differential BMEC
adhesion observed among the various prostate carcinoma cell
lines, then these differences should be manifested in varied
levels of HA retained on the surface of prostate carcinoma cells.
Therefore, we used a particle exclusion assay to visualize the
cell surface HA. In these experiments, surface-associated HA
was first amplified by addition of aggrecan, a large multivalent
proteoglycan that specifically associates with HA at the cell
surface, surrounding the cell with a highly hydrated gel-like
envelope. HA is thereby detected as a pericellular clear zone
upon addition of fixed red blood cells, which cannot settle
directly at the cell surface. Cells that lack HA do not exhibit
these cleared halos, and the blood cell particles contact the cell
perimeter. PC3M-LN4 cells were surrounded by a large matrix
FIG. 3. Enzymatic removal of HA inhibits PC3M-LN4 adhesion
to BMEC-1 but not HUVEC or BMSC. Calcein-AM-labeled PC3M-
LN4 suspensions were pretreated for 25 min at 37 °C in the absence
(solid bars) or presence (open bars) of 16 units/ml Streptomyces hyalu-
ronidase. The cells were diluted 5-fold with adhesion medium and
added to BMEC-1, HUVEC, or BMSC monolayers in a 48-well plate for
12 min at 37 °C. Nonadherent cells were removed by washing, and
adherent cells were lysed and quantified in a fluorescence plate reader.
Each bar represents the mean 6 S.E. of quadruplicate wells assayed,
reported as percentage of input cells. Each assay was repeated three
times.
FIG. 4. Adhesion of prostate carcinoma cell lines to bone mar-
row endothelial cells is differentially HA dependent. PC3,
DU145, LNCaP (A and B), and PC3M-LN4 (B) cell suspensions were
calcein-AM-labeled, pretreated in the absence (solid bars) or presence
(open bars) of 16 units/ml Streptomyces hyaluronidase. Cells were then
diluted in adhesion medium and added to confluent washed monolayers
of BMEC-1 (A), HUVEC (panel A, inset graph), or trHBMEC (B) in a
48-well plate for 12 min at 37 °C. Nonadherent cells were removed by
washing, and adherent cells were lysed and quantified in a fluorescence
plate reader. Each bar represents the mean 6 S.E. of quadruplicate
wells assayed, reported as a percentage of input cells determined sep-
arately for each cell type. Each assay was repeated three times.
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(Fig. 6A) that disappeared quantitatively after HAase treat-
ment (Fig. 6A, inset). Similarly, PC3 cell surfaces bore a matrix
(Fig. 6B) that was removed by HAase treatment (Fig. 6B, inset).
In contrast, neither DU145 cells nor LNCaP cells retained HA
on the cell surface (Fig. 6, C and D). Average ratios of matrix
area with respect to cell area, obtained by integrating individ-
ual tracings of each cell type (Table II), were 1:1 for DU145 and
LNCaP and 2:1 for PC3 and PC3M-LN4. Presence of cell sur-
face HA, therefore, correlated with rapid, specific adhesion to
BMEC. Conversely, its absence corresponded to weak
adhesion.
Prostate Carcinoma Cell HA Synthesis Correlates to Presence
of a Pericellular HA Matrix and Adhesion to BMEC—Elevated
levels of HA have been reported to correlate with progression of
several tumor types, including prostate. Furthermore, high
levels of HA synthesis are necessary and sufficient for produc-
tion of a pericellular HA coat. To address the possibility that
the prostate carcinoma cells used in our study could be synthe-
sizing large amounts of HA but differentially retaining it at the
cell surface, we quantitated the HA synthesized by each cell
line. HA synthesis occurs at the plasma membrane, concurrent
with extrusion of HA from the cell, such that the majority of
cellular HA is shed into the culture medium. Overnight culture
media from each cell type were accordingly analyzed for HA
content by a competitive binding assay and HA level was nor-
malized to cell count (Fig. 7). PC3 and PC3M-LN4 cell culture
supernatants were found to contain high levels of HA (;5 and
6 mg/106 cells, respectively, Table II) whereas DU145 culture
medium had very little (1 mg/106 cells), and levels in LNCaP
culture were virtually undetectable. These results are consist-
ent with high levels of HA synthesis contributing to cell surface
HA retention, promoting adhesion to bone marrow endothelial
cells.
Elevated Levels of HA Synthase Expression by Prostate Car-
cinoma Cells Correlate to HA Production and Adhesion to
BMEC—HA synthesis is catalyzed by one or more isoforms of
three homologous HA synthase enzymes: Has1, Has2, and
Has3. We used RT-PCR to determine initially which isoform(s)
were expressed by each prostate carcinoma cell line, in an
attempt to correlate elevated HA synthesis and BMEC adhe-
sion with presence of a specific message. We were unable to
detect Has1 message in any cell line using any set of oligonu-
cleotide primers, although we could amplify a product from a
Has1 cDNA control plasmid (data not shown). However, ex-
pression of Has2 and Has3 was detectable in most of the cell
lines. Because the presence or absence of message for a partic-
ular isoform did not appear to correlate with either HA matrix
formation or BMEC adhesion, we developed a semi-quantita-
tive approach to look at relative message levels. Equal amounts
of input mRNA from normal prostate (CLONTECH) and each
of the prostate carcinoma cell lines were reverse-transcribed
and used as templates for PCR amplification of Has2 (Fig. 8A,
lanes 8–14) or Has3 (Fig. 8B, lanes 8–14), concurrent with a
GAPDH housekeeping control message (Fig. 8, lanes 2–6).
Product yields were normalized to GAPDH and presented as
fold expression relative to normal prostate in Table II.
Results of this assay showed that PC3 (lanes 4 and 10) and
PC3M-LN4 cells (lanes 3 and 9) expressed higher levels of both
Has2 and Has3 than DU145 (lanes 5 and 11), or LNCaP (lanes
6 and 12), consistent with higher levels of HA synthesis and
rapid adhesion to BMEC by those cell lines. Has2 was virtually
absent in DU145 cells and undetectable in normal prostate
(lanes 2 and 8) or LNCaP cells. Has3 expression was dramat-
ically increased in the most highly metastatic line, PC3M-LN4,
followed by PC3 and DU145. Has3 expression was very low in
normal prostate or LNCaP cells. Although DU145 cells ap-
peared to express significant levels of Has3, this cell line was
found to be a heterogeneous population in which about 2–10%
carry surface associated HA (in contrast to PC3 and PC3M-
LN4, in which .99% of the cells carry abundant surface HA).
This was visualized by phase contrast microscopy at the level of
individual cells using biotinylated HA binding protein, followed
by streptavidin-HRP detection with diaminobenzidine precipi-
tation (data not shown). The apparent Has3 cDNA level ampli-
fied from this cell line may be anomalously high due to those
specific cells and not representative of the overall phenotype of
the cell line, which probably expresses lower message levels.
Collectively, these results demonstrate that HA synthesis cor-
relates very well to HA synthase expression level, which in
FIG. 6. Visualization of prostate carcinoma cell surface HA.
Subconfluent PC3M-LN4 (A), PC3 (B), DU145 (C), or LNCaP (D) cells
were incubated with 2 mg/ml aggrecan for 90 min, followed by addition
of 1 3 108 fixed red blood cells and incubation at 37 °C for 15 min.
HA-aggrecan coats evidenced by halos surrounding the cells were pho-
tographed at 4003 magnification. Hyaluronidase treatment eliminated
the pericellular matrices of PC3M-LN4 (panel A inset) and PC3 (panel
B inset) cells, verifying their HA composition.
FIG. 5. Effect of exogenous hyaluronan addition on PC3M-LN4
adhesion to trHBMEC. Calcein-AM-labeled PC3M-LN4 suspensions
or DU145 suspensions (inset graph) were pretreated for 25 min at 37 °C
in the absence (solid bars) or presence (open bars) of 16 units/ml Strep-
tomyces hyaluronidase. Cells were then washed and resuspended in the
indicated concentrations of hyaluronan and added to confluent mono-
layers of trHBMEC cells preincubated for 30 min in the same hyaluro-
nan concentrations. Nonadherent cells were removed after incubation
for 12 min at 37 °C and remaining adherent cells were lysed and
quantified by fluorescence plate reader. Each bar represents the
mean 6 S.E. of quadruplicate wells assayed, reported as a percentage of
input cells determined separately for each cell type.
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turn may dictate adhesion to bone marrow endothelial cells.
Furthermore, it is clear that HA synthesis and HA synthase
expression are dramatically up-regulated in aggressive pros-
tate adenocarcinoma cells, with overall HA production and
HAS expression levels correlating directly to metastatic
potential.
DISCUSSION
Bone metastasis is an eventuality of advanced stage prostate
cancer that results in severely reduced quality of life and ulti-
mate morbidity. Metastasis is preceded by initial adhesion of
circulating tumor cells to endothelial cells lining the vascula-
ture of the secondary site. Because prostate carcinoma metas-
tasizes to bone, we modeled this initial event using prostate
carcinoma cell lines and the transformed bone marrow sinus-
oidal endothelial cell lines, trHBMEC and BMEC-1. In this
study we demonstrate that highly metastatic prostate carci-
noma cells adhere to bone marrow endothelial cells through
pericellular hyaluronan (HA). Unlike reports of other model
system interactions requiring this molecule, we find that the
prostate carcinoma cells present the HA recognized by the
BMEC. The HA-mediated adhesion shows endothelial source
specificity, because PC3M-LN4 cells do not adhere rapidly to
HUVEC, another endothelial cell type. Furthermore, HA-me-
diated adhesion exhibits specificity among bone-derived cell
types: Although adhesion of PC3M-LN4 cells to bone marrow
stromal cells is rapid, HA does not appear to be involved,
suggesting other receptor interactions contribute to this proc-
ess. Up-regulation of HA synthase in prostate tumor cells may
promote bone marrow metastasis by specifically arresting
those cells on the bone endothelium.
The bone marrow microvasculature is a specialized network
of venules and fenestrated sinusoids permeable to low molec-
ular weight fluorophores but impenetrable by larger macromo-
lecular conjugates and cellular bodies (10). However, the bone
marrow as the site of hemopoiesis must be capable of progen-
itor cell flux across its protective endothelial layer, a function
not required or desirable in other types of endothelium. Endo-
thelial cell types exhibit heterogeneity in cytokine response (11,
37), receptor expression (9, 11, 36), and signaling pathways
(38). In the absence of specific stimuli, endothelial heterogene-
ity alone is able to influence homing of circulating progenitor
cells to the bone marrow through differential expression of
selectins (10, 39, 40), glycoproteins (14), and VCAM-1 and
CD44 (15). Receptor expression and adhesion of circulating
leukocytes to sites of inflammation is further regulated
through endothelial activation by inflammatory cytokines (41,
42). These cell surface differences may translate into preferen-
tial adhesion of circulating tumor cells to endothelial cells in
specific tissues.
Transformed BMEC lines recently developed have facilitated
exploration of the mechanisms by which endothelial adhesion
receptors may dictate tumor preference for specialized endo-
thelia. Results presented in this study demonstrate that pros-
tate cancer cells adhere rapidly to bone marrow but not large
vein endothelial cells. This is in agreement with observations
by other investigators that prostate adenocarcinoma cell lines
TABLE II
Elevated HA synthase expression correlates to prostate carcinoma cell surface HA, adhesion to BMEC-1, and previously reported metastatic
potential
PC3M-LN4 PC3 DU145 LNCaP
HA coata 1.94 6 0.03 1.89 6 0.04 1.02 6 0.02 1.01 6 0.01
HA synthesisb 6.38 6 1.01 4.74 6 0.61 1.19 6 0.41 0.64 6 0.21
HAS expressionc
Has2 2 6 0.2 0.1
Has3 20 17 10 0.5
BMEC adhesiond 71 6 2 65 6 8 24 6 2 26 6 3
Metastatic potentiale High High Moderate Low/none
a Pericellular clear zones and cell perimeters of 20 individual cells were traced in NIH IMAGE, the relative ratio was calculated, and the
corresponding ratio for HAase treated cells was subtracted. A value of 1 denotes a cell completely lacking pericellular matrix.
b Values presented are those plotted in Fig. 7 (in micrograms per 106 cells).
c Derived from Fig. 8. Data are shown as -fold expression relative to levels in normal prostate, normalized to GAPDH.
d Presented as percentage of input cells. The value for PC3M-LN4 cells is extracted from Fig. 2, and the other values from Fig. 4A.
e Cited in “Discussion.”
FIG. 7. HA synthesis and secretion by prostate carcinoma cells
in culture. Equal numbers of prostate carcinoma cells were seeded
overnight then given fresh culture medium. After an additional 24 h,
supernatants were harvested and cells were trypsin-released and
counted. HA-containing culture media were serially diluted, incubated
with biotinylated HA binding protein, and applied to HA-coated plates.
Bound HA binding protein was detected, following extensive washes,
with streptavidin-HRP conjugate and OPD substrate, and quantified
spectrophotometrically. Total HA in the culture media was determined
by interpolation from a concurrent HA standard curve and plotted
relative to cell number in the original culture.
FIG. 8. HA synthase expression in prostate adenocarcinoma
cell lines. HA synthase isoform and level of expression was determined
for each of the four prostate carcinoma cell lines PC3M-LN4, PC3,
DU145, and LNCaP, and for normal prostate, by RT-PCR as described
under “Experimental Procedures.” A, RT-PCR amplification of Has2
and GAPDH control messages; B, Has3 and GAPDH. Anticipated prod-
uct sizes (in base pairs) are indicated adjacent to the figure: Has2 is
;210 bp, Has3 is ;410 bp, and GAPDH is ;980 bp. Lanes are num-
bered as follows: lanes 1 and 7, 100-base pair DNA ladder; lanes 2 and
8, normal prostate; lanes 3 and 9, PC3M-LN4; lanes 4 and 10, PC3;
lanes 5 and 11, DU145; lanes 6 and 12, LNCaP; lane 13, Has2 control
plasmid; lane 14, Has3 control plasmid.
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adhere preferentially to cell cultures enriched for BMEC over
components of the bone marrow or hepatic endothelial cells (2).
In another study, adhesion of prostate carcinoma cells to a cell
line immortalized from isolated BMEC was shown to be inhib-
ited by preincubation of BMEC with monoclonal anti-LFA-1
antibodies or polyclonal anti-galectin-3 (43), but it was unclear
which cell type expressed LFA-1 because neither has been
previously reported to do so. We have used two transformed
bone marrow endothelial cell lines, BMEC-1 (30) and trHBMEC
(11), which express the same cell adhesion molecules and syn-
thesize the same cytokines as the primary endothelial cells
with minor differences in level of expression, to determine that
HA on the prostate tumor cells mediates adhesion to BMEC.
However, this does not exclude the possibility of other interac-
tions. We expect that, like progenitor arrest, adhesion and
migration of prostate tumor cells on BMEC involves multiple
adhesive interactions that may or may not be interdependent.
HA is a ubiquitous polysaccharide component of extracellu-
lar and cell-associated matrices (44, 45), essential for growth
and motility. HA is required for normal ductal branching in the
developing prostate gland (46), underscoring its vital role in
cell migration (47). In some cell types, this requirement entails
assembly of an HA pericellular matrix for proliferation and
migration (33, 48). Cell-associated HA may facilitate growth
and motility by stimulating detachment of rounded, dividing
cells and the trailing edges of migrating cells, respectively. HA
exhibits further functional complexity as an adhesion molecule
involved in recruitment of circulating lymphocytes to inflamed
tissues through the action of cell surface HA receptors (38). The
structure of HA, consisting of many thousand repetitions of a
disaccharide motif, is well-suited to serve as a multivalent
ligand for coordinate binding by many simultaneous adhesion
receptors or for providing a scaffold for cellular movement.
Cellular behaviors contributing to cancer progression in-
clude unrestricted growth, motility, and ability to circulate and
colonize new tissues. Because HA is a normal component of
such processes, it is not surprising that elevated levels corre-
late with cancer progression (21, 49, 50). High levels of serum
HA, for example, correlated with disseminated carcinoma in
general (51, 52) and, specifically, with tumor progression to
metastatic disease in malignant lymphoma (53) and breast
carcinoma (54). In human breast carcinoma, HA is more con-
centrated in areas where the tumor is invading into the sur-
rounding tissue (22), and elevated stromal and cell-associated
HA correlates with malignancy (55). Elevated stromal and
epithelial HA are also indicative of poor survival rate in pa-
tients with ovarian and colorectal cancers (23, 24). In animal
models, tumor cells with high levels of HA expression were
more metastatic than cells expressing lower levels of HA (27,
29, 56, 57). Interestingly, both high and low HA-expressing
cells have the same growth rate in vitro and at the primary
injection site (27). This correlation of HA with metastasis but
not growth rate suggests that HA may be more critical to
endothelial adhesion and/or the infiltration of the cells into
tissues.
PC3M-LN4 cell adhesion to BMEC in vitro was both en-
hanced and inhibited by the addition of high molecular weight
HA. At low concentrations comparable to those secreted into
the culture medium of the cells during growth, adhesion of
hyaluronidase-treated tumor cells to BMEC was significantly
enhanced by HA preincubation. HA prebinding by the BMEC
may restore adhesion by replacing the cross-bridging ligand
normally presented by the prostate tumor cells via its own cell
surface HA receptors. When BMEC were precoated with higher
levels of HA, PC3M-LN4 cell adhesion was almost entirely
precluded, regardless of HAase treatment. This suggests that
BMEC and prostate HA receptors have been saturated and are
no longer able to cross-link. HA has been previously reported to
enhance/inhibit intercellular adhesion in this fashion in devel-
opment of chick limb buds (58). Rapid intercellular adhesion
was synergistically inhibited by HAase treatment and high
exogenous HA, suggesting the incomplete HAase effect is prob-
ably due to HA resynthesis during the assay. By contrast,
DU145 cell adhesion was not affected by addition of HA at any
concentration, and therefore, these cells most likely lack active
cell surface HA binding proteins.
PC3 (59) and PC3M-LN4 (35) prostate carcinoma cells are
highly metastatic in mouse models and are shown in this report
to produce a dense pericellular HA matrix that mediates adhe-
sion to bone marrow endothelial cells. DU145 (60) and LNCaP
(61) cell lines, by contrast, are poorly metastatic in mice, pro-
duce very little HA, and do not adhere well to BMEC. It is
worth noting the origins and characteristics of the four cell
types: PC3 is from a human bone metastasis; its derivative,
PC3M-LN4, metastasizes to mouse bone; DU145 and LNCaP
are from a human brain and a human lymph node metastasis,
respectively, and their interaction with bone has never been
documented. The correlation between high metastatic potential
as reported in the literature, up-regulated HA synthesis and
expression of HA biosynthetic enzymes is summarized in Table
II. This correlation is consistent with a putative role for HA as
a component of prostate cancer metastasis. In fact, HA over-
production is thought to be directly involved in prostate cancer
progression. Histological sections of normal adult prostate tis-
sue demonstrate the presence of HA in the prostate stroma (25,
46). In cancerous human prostates, HA expression levels are
increased on the carcinoma cells and correspond to dedifferen-
tiation of the cancer (25, 26).
Synthesis and secretion of HA is catalyzed in vertebrates by
a family of three HA synthases: Has1 (62), Has2 (63), and Has3
(64), each of which is capable of conferring HA synthesis and
pericellular HA retention to transfected cells (for a review of
HA synthases, see Ref. 65). HAS expression is ubiquitous, but
isoforms exhibit temporal and tissue-specific distribution. Tar-
geted disruption of the has2 gene is an embryonic lethal mu-
tation in mice, which fail to produce HA essential for pericar-
dial endothelial cell migration and endothelial/mesenchymal
transformation during cardiac development (66). Has2 is also
specifically up-regulated in response to wounding in a mesothe-
lial cell model (67). Because HAS expression is critical during
periods of normal tissue remodeling, understanding its dys-
regulation in tumors may be important in controlling tumor
growth and metastasis. HAS expression is regulated by glu-
cocorticoids (68), growth factors such as platelet-derived
growth factor (69), transforming growth factor b1 (70), and
pro-inflammatory cytokines (71). Expression of HAS appears to
correlate directly to HA synthesis (69), suggesting regulation
occurs at the level of transcription. To date, there is no evidence
for post-transcriptional mechanisms. Elevated HA in tumor
cells is, therefore, probably a reflection of HAS gene expression.
In support of this, we have determined that Has2 and Has3 are
strongly up-regulated in highly metastatic prostate tumor
cells. HAS up-regulation in prostate cancer progression may be
dictated in part by factors such as those described above, pro-
duced and secreted by prostate stromal or epithelial cells.
HA synthase enzymes have been implicated in tumorigene-
sis and metastasis in mouse models. Overexpression of Has2 in
fibrosarcoma cells yields significantly larger subcutaneous tu-
mors (28). Mammary carcinoma cells transfected with has1
were more metastatic than control cells (29). In a melanoma
model, tumor cells selected for high cell surface expression of
HA were highly tumorigenic and metastatic, whereas tumor
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cells bearing little or no surface HA, although equally tumori-
genic, did not metastasize (27). In the latter model, however,
has isoform expression was not characterized. Our data pres-
ent the first characterization of has expression in prostate
carcinoma cells and reveal a possible correlation of Has3 over-
expression with tumor cell metastatic potential. Collectively,
these results suggest involvement of HA in tumor growth and
metastasis, and imply that specific HA synthase isoforms
and/or expression levels of those isoforms may mediate these
processes.
Both Has2 and Has3 are capable of synthesizing HA with an
average molecular mass of 1–2 million Da (72), the average size
of the exogenous HA used to enhance/inhibit adhesion (Fig. 5).
This would suggest that the products of both enzymes are
capable of supporting intercellular adhesion. DU145 cells, how-
ever, appear to express elevated Has3 but synthesize little HA
and retain no matrix. One possible explanation may be that
Has3 message is transcribed but not translated in these cells or
that the protein made is inactive. Alternatively, there may be a
requisite maximum threshold of HAS expression for mainte-
nance of a pericellular matrix. Levels of Has3 expression suf-
ficient to promote matrix retention may occur in only a subset
of DU145 cells, with the remaining cells expressing it at lower
levels. This may also be the case for Has2 expression. If pro-
duction of an HA matrix enhances arrest in the bone marrow
sinusoids, the cell population would have significantly dimin-
ished propensity to do so, relative to PC3 or PC3M-LN4 cells,
which could then translate to reduced bone metastatic procliv-
ity. Both enzymes are up-regulated in highly metastatic cells,
which may implicate HAS up-regulation in prostate cancer
progression. Has3 overexpression most consistently corre-
sponds to aggressive potential, but intrinsic heterogeneity
within the cell lines renders assignment of such a correlation
premature.
Another factor to consider is that DU145 cells may lack
surface receptors to anchor the matrix, because exogenous HA
could restore adhesion of HAase-inhibited PC3M-LN4 cells,
which are normally able to maintain an HA coat, but not
enhance adhesion of DU145 cells. It is important to recognize
that, although HA produced by prostate tumor cells may facil-
itate metastasis to bone marrow by initially attaching to the
endothelium in the bone marrow, changes in matrix-associated
HA binding proteins could also modify prostate tumor cell
behavior. Because HA is secreted as a free glycosaminoglycan
and is not attached to a core protein, its retention at the cell
surface is achieved through accessory proteins such as versi-
can, which contribute to the matrix, specifically binding and
cross-linking the multivalent HA into a dense network (33, 48).
Elevated levels of versican are associated with prostate carci-
noma progression, but it is not known if its HA binding properties
are responsible (73).
However, in addition to the HA binding proteins in the
extracellular matrix, HA is specifically recognized by a widely
expressed transmembrane receptor, CD44. Bone marrow and
umbilical vein endothelial cells BMEC-1, trHBMEC, and
HUVEC express cell surface CD44 but exhibit different affinity
for PC3M-LN4 cells. Preincubation of BMEC-1 cells with var-
ious reported anti-CD44 blocking monoclonal antibodies failed
to impact prostate tumor cell interaction (data not shown).
Nonetheless, regulation of CD44 activation state with respect
to HA binding occurs on many levels and probably contributes
to endothelial adhesive preference. CD44 and HA interactions
may be important for metastasis. CD44-mediated migration
and invasion of glioma cell lines is stimulated by HA (74) and
inhibiting CD44/HA interactions in vivo inhibits metastasis
(75, 76). HA clusters CD44 resulting in stimulation of signal
transduction pathways and engagement of adhesion molecules
such as integrins (77), which could either strengthen adhesion
or lead to transmigration of the prostate cells through the
endothelium.
Alternatively, HA binding proteins on the surface of BMEC-1
other than CD44 may contribute to rapid adhesion. One can-
didate protein is the receptor for HA-mediated motility
(RHAMM), which has not been reported on BMEC surfaces but
has been shown to mediate differential HA binding by endo-
thelial cells of different vascular origin (36). It is therefore
possible that differences in vascular endothelial RHAMM ex-
pression could be promoting the recognition of prostate carci-
noma cells bearing surface-associated HA. Other recently de-
scribed cell surface HA receptors include the lymph vessel
endothelial-specific LYVE-1 (78), and the HA receptor for en-
docytosis thought to be specific for clearance of circulating HA
through the liver and spleen (79).
In this report, we have surveyed established prostate carci-
noma cell lines for common molecular interactions governing
preferential adhesion to bone marrow endothelial cells and
discovered a correlation between metastatic potential and ele-
vated HA synthase. We have delineated a mechanism in which
prostate cancer cells adhere to bone marrow endothelial cells
via tumor cell-associated HA. It will be important to extend
these findings to establish whether this adhesive interaction
contributes to prostate cancer metastasis. With this goal, we
are currently manipulating HA levels on prostate carcinoma
cells in HA synthase transfectants, which should enable us to
determine if HA changes the metastatic potential of prostate
carcinoma cells in an animal model and whether a specific HA
synthase isoform is responsible. Furthermore, this approach
will allow us to study the impact of HA overproduction on
activation of adhesion receptors and signal transduction path-
ways in HA-mediated adhesion of prostate carcinoma cells to
bone marrow endothelium.
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